CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the management team will participate in two upcoming investor conferences in April 2023.
| SEATTLE, Wash., April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two upcoming investor conferences in April 2023. 22nd Annual Needham Virtual Healthcare Conference Stifel 2023 Targeted Oncology Days (Virtual) A link to the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. About CTI BioPharma Corp. CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com. VONJO® is a registered trademark of CTI BioPharma Corp. Investor Relations and Media Contacts: Remy Bernarda
SOURCE CTI BioPharma Corp. | ||
Company Codes: NASDAQ-SMALL:CTIC |
View original content to download multimedia:
